submit to the journals

ADA Highlights

flipper_slider

Editor's Choice

Chantal Mathieu discusses the outcomes of the EMPA-REG, LEADER and SUSTAIN-6 trials on diabetes treatment. Part 1 of 2 View Part 2 here.

ADA Highlights Videos

In an informative interview with Touch Medical Media, Dr Buse discusses the latest developments in continuous glucose monitoring, insulin and adjunctive treatments in type 1 diabetes. There is particular focus on the two pivotal inTandem1 and inTandem2 studies for sotagliflozin in patients with...
In this interview, Dr Lu Qi (Chair, Department of Epidemiology, Tulane University, New Orleans, LA, US) discusses the affect our genetic makeup can have on our diet and disease progression and treatment. He explains that while research is still in the early stages, he hopes that we can use...
Barbora De Courten (Associate Professor at Monash University, Melbourne, Australia) discusses the latest studies into carnosine supplementation in diabetes prevention at ADA 2018. Carnosine is food supplement and has been shown in animal studies to prevent and be useful in the treatment of type 2...
We met with Dr Amy E Rothberg (Associate Professor, School of Public Health, University of Michigan, Ann Arbor, MI, US) at the ADA 2018 meeting to discuss the OPTIWIN study and OPTIFAST program. The OPTIWIN study was a randomized controlled trial which compared the effectiveness of a meal-...
In this interview with Dr Robert Ryder (Sandwell and West Birmingham NHS Trust, City Hospital, Birmingham, UK), he explains how the EndoBarrier device works and how it aids weight loss and glycemic control in patients with diabetes. Those who would benefit from this device typically have a long...
Dr Michael Lean (Chair of Human Nutrition [Medicine], University of Glasgow, Glasgow, UK) reviews the Diabetes Remission Clinical Trial (DiRECT). Weight loss is the most important thing patients can do to reduce glycated hemoglobin, reduce/eliminate comorbidities, and eventually gain diabetes...
Dr Arturo Vegas (Assistant Professor of Chemistry, Boston University Centre for Molecular Discovery, Boston, MA, US) explains the fundamentals of nanotechnology and how this can be applied to the treatment of type 1 and type 2 diabetes. He also discusses “smart” insulins, which are more glucose...
touchENDOCRINOLOGY meets with John Doupis to discuss mobile intelligence in diabetes therapy.
Stefano Del Prato discusses the use of DPP-4 inhibitors and vildagliptin in special patient populations. Read more in European Endocrinology here. Support: The filming of this video was supported by Novartis. Stefano Del Prato has received research support from AstraZeneca, MSD, Novartis and...
W David Strain and Päivi Maria Paldánius discuss the post-authorisation programme for vildagliptin and clinical evidence for the optimised management of chronic diseases beyond type 2 diabetes. Read more in European Endocrinology here. Support: The filming of this video was supported by Novartis...
Bo Ahrén and James Foley discuss the Initiation of the Novartis GLP-1 based therapy programme the development of vildagliptin over the past 10 years. Read more about it in European Endocrinology here. Support: The filming of this video was supported by Novartis. James Foley is an employee and...
Chantal Mathieu and Päivi Maria Paldánius discuss the development pathway of DPP-4 inhibitors and vildaglipin. Read more in the recent publication in European Endocrinology here. Support:The filming of this video was supported by Novartis. Päivi Maria Paldánius is an employee of Novartis....